康希诺生物

Information Disclosure

Home >Investor Relations >Information Disclosure

H Share

Letter to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications and Reply Form
Letter to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications and Reply Form
Monthly Return of Equity Issuer on Movements in Securities
VOLUNTARY ANNOUNCEMENT INITIATION OF PHASE I CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT FOR ABSORBED TETANUS VACCINE
VOLUNTARY ANNOUNCEMENT INITIATION OF PHASE I CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT FOR TDCP ADOLESCENT AND ADULT
VOLUNTARY ANNOUNCEMENT RECOMBINANT COVID-19 XBB.1.5 VARIANT VACCINE FOR INHALATION (ADENOVIRUS TYPE 5 VECTOR) INCLUDED FOR EMERGENCY USE
Monthly Return of Equity Issuer on Movements in Securities
VOLUNTARY ANNOUNCEMENT INITIATION OF PHASE I CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT FOR RECOMBINANT ZOSTER VACCINE
RESIGNATION OF CHIEF FINANCIAL OFFICER
Monthly Return of Equity Issuer on Movements in Securities

1 12 13 14 15 16 52